Salute e Benessere

OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and…

OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancerby Dr Stephen Liu and Prof Benjamin BesseNANTES, France, June 12, 2024 – 6:00pm CETIn this webinar, OSE Immunotherapeutics joins key opinion leadersDr Stephen Liu, associate professor and director of Thoracic Oncology at Georgetown University Lombardi Comprehensive Cancer Center (Washington DC, United States) andProf Benjamin Besse, medical oncologist...
Nasdaq GlobeNewswire
12/06/2024

Aktiia Receives Regulatory Approval for the World's First Optical Blood Pressure…

The healthcare industry is already taking note: "The ability to monitor blood pressure without using a cuff is a game-changer. This achievement has the potential to greatly improve hypertension care, from better patient motivation to more efficient medication regimens," said Adrian James, former President of Omada Health. The healthcare industry is already taking note: " The ability to monitor blood pressure without using a cuff is a game-changer. This achievement has the…
PR Newswire
12/06/2024

Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking…

Presented recently at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) presented two abstracts related to their novel immunotherapy, pelareorep, an intravenously delivered immunotherapeutic agent. Presented recently at the 2024American Society of Clinical Oncology (ASCO)Annual Meeting,Oncolytics Biotech Inc.(NASDAQ: ONCY) (TSX: ONC)presented two abstractsrelated to their novel immunotherapy, pelareorep, an...
PR Newswire
12/06/2024

Vaccines Market to be Worth $71.50 billion in 2031- Exclusive Report by…

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. Vaccines activate the immune system without making us sick. Many dangerous infectious diseases can be prevented in this simple and effective way. Also, immunization is a way to build our body's natural immunity against disease. The market's growth is driven by the strong pipeline for vaccines, increasing government initiatives toward immunization, and technological advancements in the…
PR Newswire
12/06/2024

Veterinary Ophthalmology Equipment Market Hits $485M in 2024, Anticipates 7.5%…

Browse in-depth TOC on "Veterinary Ophthalmology Equipment Market" Browse in-depth TOC on "Veterinary Ophthalmology Equipment Market" 336 - Tables 66 - Figures 319 - Pages Market Drivers: Rising Pet Ownership and Expenditure The surge in pet ownership, amplified by increasing income levels, demographic shifts, and the impact of the COVID-19 pandemic, is propelling the demand for specialized veterinary services, notably in ophthalmology. This heightened awareness of pet...
PR Newswire
12/06/2024

Avicenna.AI secures FDA clearance for AI detection of vertebral compression…

Often resulting from the deterioration of bone structure (osteoporosis), VCFs can cause significant pain, deformity, and height loss. In the USA, approximately 750,000 adults suffer from osteoporotic VCFs each year, but around two-thirds of those go undetected or unreported. Often resulting from the deterioration of bone structure (osteoporosis), VCFs can cause significant pain, deformity, and height loss. In theUSA, approximately 750,000 adults suffer from osteoporotic VCFs each year, but...
PR Newswire
12/06/2024

Ansell Recognized with the Frost & Sullivan 2024 Global Company of the Year…

Ansell is deeply committed to ensuring the safety and well-being of workers with its highly advanced personal protection equipment and safety solutions. Their customer-centric approach is exemplified through innovative solutions like the Worker Experience Innovation platform and exceptional educational support services such as AnsellCARES. Ansell offers groundbreaking technologies, especially in the form of two significant technologies, ERGOFORM, and PI-KARE, which are designed to protect…
PR Newswire
12/06/2024

ELFBAR and LOST MARY redefine next-gen vaping at World Vape Show 2024

"We can't wait to share our latest R&D results in products with adult users worldwide, including those in the Middle East," said Jacques Xiang Li, spokesperson for ELFBAR and LOST MARY. "We can't wait to share our latest R&D results in products with adult users worldwide, including those in theMiddle East," saidJacques Xiang Li, spokesperson for ELFBAR and LOST MARY. "We've been turbocharging the effort to align products more with the users' cessation journey…
PR Newswire
12/06/2024

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted…

Clinical trial to evaluate the safety and efficacy of OBI-992 in advanced solid tumors. /2 clinical trial of OBI-992, an antibody-drug conjugate (ADC) targeting TROP2 (Trophoblast cell-surface antigen 2), an antigen overexpressed in multiple tumor types. OBI plans to enroll patients with advanced solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer (GC), and other potential cancers. The objective of the trial is to verify the safety,...
Nasdaq GlobeNewswire
12/06/2024

Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to…

Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO ®in the UK and IrelandLugano, Switzerland – June 12, 2024– Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, and Chugai Pharma Europe Ltd (“Chugai”), the European subsidiary of Chugai Pharmaceutical Co, Ltd., one of Japan's leading...
Nasdaq GlobeNewswire
12/06/2024

DoH and Penn Medicine to expand collaboration on translational research and…

Through this MoU, DoH and Penn Medicine seek to design and develop a translational medicine ecosystem based on Penn'sInstitute for Translational Medicine and Therapeutics (ITMAT). In addition, the MoU seeks to explore the potential of launching two multi-year collaborative research programmes. One focuses on the expanded application of artificial intelligence to identify new potential antibiotics. The other focuses on longitudinal follow-up and genetic analysis of people with Alzheimer's in Abu…
PR Newswire
12/06/2024

Senior life science and medical specialists join SmartCella's Board of Directors

At the Annual General Meeting, Anna Martling (Professor of Surgery and Scientific Director Life Science at Karolinska Institutet), Claude Dartiguelongue (previously senior roles with Lonza, Thermo Fisher Scientific and Becton Dickinson and Company), and Regina Fritsche-Danielson (PhD in Cardiovascular Physiology/Pharmacology and Senior Vice President and Global Head of Research and Early Development, Cardiovascular, Renal and Metabolic Diseases at AstraZeneca) were appointed new members of the…
PR Newswire
12/06/2024

TELUS Mental Health Index: 44 per cent of workers feel exhausted after work…

"There is no question that AI's advancement will bring significant benefits, potentially as pivotal as the industrial or internet age," said Paula Allen, Global Leader, Research & Client Insights, TELUS Health. "Organizations have the opportunity to engage employees in this evolution by ensuring that AI tools and training are readily accessible to employees, and enabling them to explore the technology firsthand so they can discover the ways it benefits them in their own work…
PR Newswire
12/06/2024

Insider Information: Nexstim Plc Provides Further Details on Technology License…

Company announcement, Helsinki, 12 June 2024 at 9 AM (EEST) Insider Information: Nexstim Plc Provides Further Details on Technology License Agreement with Magnus Medical, Inc. Nexstim Plc (NXTMH:HEX) (“Nexstim” or “Company”) announces that it has disagreements regarding the licensing of the Company's technology to medical technology company Magnus Medical, Inc. (”Magnus Medical”). The technology licensed is related to the NBT® system developed by the Company, with certain restrictions,...
Nasdaq GlobeNewswire
12/06/2024

Crossject appoints Dan Chiche, MD as Chief Medical Officer North America

Brings extensive experience in drug development in the U.S and internationally and in maximizing value of medical productsReinforces leadership team and expands presence in North AmericaSupports processes targeting ZEPIZURE® regulatory milestones in the U.S. in 2025Dijon, France 12 June 2024, 7:30 am CET- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE®, its emergency treatment for the...
Nasdaq GlobeNewswire
12/06/2024

BioSenic to host Annual General Meeting on July 12, 2024

PRESS RELEASE – REGULATED INFORMATIONPreliminary documents for the Annual General Meeting have been made available on company's websiteMont-Saint-Guibert, Belgium, June 12th, 2024 7.00am CET –BioSenic(Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the annual...
Nasdaq GlobeNewswire
12/06/2024

Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with…

®, product code: JS001), in combination with bevacizumab for the first-line treatment of advanced hepatocellular carcinoma (“HCC”) has met the pre-defined efficacy boundary. Junshi Biosciences plans to submit a supplemental new drug application (“NDA”) for this indication to the regulatory authorities in the near future. Liver cancer is a common malignant tumor of the digestive system worldwide, and the predominant pathological type is HCC (accounting for about 90%). According to the...
Nasdaq GlobeNewswire
12/06/2024

UAE Workplaces Still Most Engaged In MENA Region; Surging Confidence In The…

These rates outpace the global average of 23% and are well above the average 14% employee engagement rate in the MENA region. Notably, engagement rates are similar for employees across age groups. However, fewer employees older than 35 (56%) are not engaged, compared to 62% of not engaged employees younger than 35. These rates outpace the global average of 23% and are well above the average 14% employee engagement rate in the MENA region. Notably, engagement rates are similar for employees...
PR Newswire
12/06/2024

Novo Nordisk Foundation and the Wellcome Trust award a grant of up to DKK 585…

AEGIS is led by the evolutionary geneticist Professor Eske Willerslev from the University of Copenhagen and University of Cambridge. The initiative aims to decode and understand how ecosystems and crops have responded and adapted to past environmental perturbations and is driven by the aspiration to create a more sustainable future by enhancing crop resilience and agroecosystem sustainability. AEGIS is led by the evolutionary geneticist Professor Eske Willerslev from theUniversity of...
PR Newswire
12/06/2024

Global Anti-Radiation Drugs Market to Register Incremental Growth at a CAGR of…

Key Takeaways from the Anti-Radiation Drugs Market Report Key Takeaways from the Anti-Radiation Drugs Market Report To read more about the latest highlights related to the anti-radiation drugs market, get a snapshot of the key highlights entailed in theGlobal Anti-Radiation Drugs Market Report Anti-Radiation Drugs Overview Anti-radiation drugs are pharmaceutical compounds designed to mitigate the damaging effects of radiation exposure on the human body. These drugs work by...
PR Newswire
11/06/2024

Voting Rights and Shares Capital of the Company

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, June11, 2024(GLOBE NEWSWIRE) --Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights,...
Nasdaq GlobeNewswire
11/06/2024

Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in…

Recognized by the FDA as an excellent model for toxicology, small breeds of miniature domestic pigs known as minipigs share strong similarities with humans in crucial aspects such as drug metabolism, skin structure, genetics, and physiological mechanisms. In this preliminary safety study, minipigs received a single subcutaneous injection of LPT-CBD and were closely monitored for pharmacokinetics and basic safety parameters over one month. Encouragingly, the animals all exhibited good...
PR Newswire
11/06/2024

Transactions with shares and linked securities in Genmab A/S made by managerial…

Company Announcement COPENHAGEN, Denmark; June 11, 2024 –Genmab A/S(Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish...
Nasdaq GlobeNewswire
11/06/2024

Last patient in: Laminar Pharmaceuticals S.A. completes recruitment for…

"We are pleased to announce that the pivotal phase 2b/3 trial recruitment is completed, as this means that the results and outcome of the trial will be soon available," said Adrian McNicholl, Chief of Clinical Operations at Laminar Pharmaceuticals. The trial is expected to reach the trigger event for interim analysis in July 2024, which would provide an unblinded readout the last quarter of this year. "If idroxioleic acid is able to show compelling evidence demonstrating…
PR Newswire
11/06/2024
Altri  Comunicati